Tuberculosis (TB) is an infectious disease, caused by an extremely slow growing bacterial pathogen belonging to the Mycobacterium tuberculosis complex. 1 Among them, M. tuberculosis is responsible for the majority of human deaths. 2 It is estimated that at least one-third of the world's population is latently infected with the bacteria that causes TB, while in 2012, WHO reported 8.6 million new cases of the disease and 1.3 million deaths due to it, worldwide. 3 Lengthy treatment regimens have as a consequence, the rise of drug resistant TB-causing strains. This has set the alarm for controlling the disease, which necessitates the discovery of new therapeutic targets and synthesis of novel inhibitors.
In order to specifically inhibit mycobacterial growth, alternative metabolic pathways, exclusive to the bacteria, need to be targeted for an efficient anti-TB drug development programme. 4 In this regard, we focused our interest on the genome of M. tuberculosis, which has been reported to contain a thyX gene (Rv2754c), encoding the ThyX protein, a flavindependent thymidylate synthase responsible for the de novo synthesis of 2' -deoxythymidine 5'-monophosphate (dTMP), a key precursor of DNA. 5 ThyX, present primarily in prokaryotes and viruses, is rare in eukaryotes and absent in humans, where the corresponding metabolic function is carried out by the conventional ThyA protein. Both the enzymes catalyze the reductive methylation of 2'-deoxy-uridine-5'-monophosphate (dUMP) to dTMP in the presence of methylenetetrahydrofolate; however, based on their structural and catalytic dissimilarities, different enzymatic mechanisms have been suggested for each. 6 In contrast to ThyA, where methylenetetrahydrofolate acts both as the carbon donor and reducing agent, ThyX uses methylenetetrahydrofolate as the one-carbon donor molecule and reduced flavin adenine dinucleotide (FADH 2 ) as a cofactor that serves as the hydride donor. 7 Micro-organisms contain either ThyA or ThyX; however, mycobacteria encode both ThyA and ThyX. However, a sequence similarity search yielded no significant matches between ThyX of mycobacteria to the ThyA of other eukaryotic cells. Recently, functional studies, devoted to investigate the biological role of both of these enzymes, showed that ThyX is essential for the survival of M. tuberculosis even in the presence of ThyA and exogenous thymidine. 8, 9 M. tuberculosis cannot utilize exogenous thymidine sources because it lacks thymidine kinase, the essential enzyme for the conversion of thymidine into dTMP. 5 All these factors support the existence of ThyX enzyme as a prospective therapeutic target for the development of a new selective anti-tubercular drug treatment. 10 The chemical class of C5-alkynyl substituted 2'-deoxyuridine-5'-monophosphate (dUMP) has been reported as selective inhibitor of ThyX in M. tuberculosis. 11 In this study, among several compounds, N-(3-(5-(2'-deoxyuridine-5'-monophosphate))prop-2-ynyl)octanamide 1 (figure 1) was identified as the most potent and selective analogue with an IC 50 value of 0.91 M versus recombinant ThyX from M. tuberculosis. However, the polarity of this compound constitutes a major obstacle for its penetration through the complex mycobacterial cell wall. Indeed one of the major challenges for chemotherapeutic drugs is associated with difficulties in crossing the thick, lipid-rich cell wall of the mycobacteria, which prevents their permeation, with a consequential poor biological response. In particular, the permeation of hydrophilic compounds is not very efficient due to the presence of low numbers and the exceptional length of porins, water-filled open channels, responsible for mediating the diffusion of hydrophilic nutrients. 12 Moreover, the existence of active drug efflux pumps reduces the concentration of active molecules inside the bacterial cell and their up-regulation has been suggested to contribute to the emergence of drug resistance. 13 To the contrary more lipophilic drugs are more likely to diffuse through the lipid-rich environment of the mycobacterial cell wall. In addition to high polarity, the instability of 1 in biological media, a well-known drawback for free nucleoside phosphates, may also limit its therapeutic potential, with dephosphorylation likely exceeding cell permeation.
To improve stability, permeability and therefore antibacterial activity, lipophilic prodrugs of 1 are thus required. Among several strategies developed to overcome these issues, our phosphoramidate ProTide approach was selected for this study. 14, 15 This technology consists of masking the negative charges of the phosphate group with an aromatic moiety and an amino acid ester. To date, this approach has been widely applied mainly to antiviral 16 and anticancer nucleoside analogues 17 and more recently also to N-acetyl glucosamine to treat osteoarthritis. 18 Typically, two enzymatic cleavages are involved in the cellular bio-activation of antiviral and anticancer ProTides, either in the viral infected or human cancer cell. 19 Firstly, a carboxypeptidase-type enzyme may mediate the cleavage of the ester moiety. This step is followed by a spontaneous intramolecular cyclisation with the subsequent release of the aryl moiety and formation of an unstable mixed cyclic anhydride which undergoes ring-opening mediated by water to release a mono ester phosphate prodrug. In the last step, a phosphoramidase-type enzyme, most probably a human Hint-1, may be responsible for the cleavage of the phosphorus-nitrogen bond with the consequent release of the monophosphate.
Since we wanted to investigate whether phosphoramidates of 1 are capable of crossing the cell wall of mycobacteria and to be bio-converted into the monophosphate once inside, herein we report the synthesis of several derivatives and their biological evaluation against the TB vaccine strain, M. bovis BCG and the virulent TB causing lab strain, M. tuberculosis H37Rv, using HTSPOTi, a rapid but gold standard whole-cell phenotypic assay. This is the first time that the application of the ProTide technology has been reported for improving the antimicrobial activity of inhibitors of a protein target of M. tuberculosis. The Prodrugs were prepared by chemical modification of nucleoside 2 rather than directly modifying compound 1 (see Scheme 1) . As ThyX proteins are also found in several doublestranded DNA viruses 5 and considering that some 5-alkynyl-2′-deoxyuridine analogues, in addition to their anti-TB activity [20] [21] [22] showed significant antiviral activity 23 we also report the antiviral evaluation of the parent nucleoside of 2 and its prodrug monophosphate derivatives.
Results and Discussion

Chemistry
The phosphoramidates 7a-l described in this study are shown in Table 1 with the reaction sequence for their synthesis summarized in Scheme 1. Our synthetic efforts started with the synthesis of the propargyloctylamide 4 from propargylamine 3 and octanoyl chloride. 11 Then, Sonogashira cross coupling 24 of the commercially available 5-iodo-2'-deoxyuridine 5 with alkyne 4 afforded the desired nucleoside 2, isolated in excellent yield (91%) without column chromatography purification. It is noteworthy to mention that our synthetic procedure to the preparation of 2 was made less time-consuming than the previously reported procedure, with great improvement in terms of yield achieved. 11 Following the general synthetic procedure for compounds 7a-l, nucleoside 2 was reacted with the appropriate phosphorochloridate 6a-l using N-methylimidazole as activator, according to a previously described method. 25 The desired phosphoroamidates 7a-l were obtained from 5 to 39% yield. Yield optimization was beyond the scope of the work as we were in the early stages of establishing biological activity and potential lead molecules. 
Antimycobacterial specificity
All synthesized compounds 7a-l and nucleoside 2 were evaluated in vitro against M. bovis BCG and, M. tuberculosis H37Rv using the HT-SPOTi assay 26 at 1-250 mg/L concentrations. This wholecell assay was indicative toward inherent resistance, such as cell wall impermeability. In order to evaluate a specific endogenous mechanism of anti-mycobacterial action for these compounds via ThyX inhibition, we also tested their biological activity against E. coli, a Gram-ve bacterium where a functional ThyX homologue is missing from the genome. The minimum inhibitory concentrations (MIC) of compounds that completely inhibited growth of both mycobacterial strains are shown in Table 2 .
The highly hydrophilic nucleoside 2 (ClogP = -0.21) did not exhibit antimycobacterial activity with a MIC> 250 mg/L ( Table  2) . For the first series of phosphoroamidates bearing a naphthyl group as an aromatic part (7a-d), a structure-activity relationship (SAR) was found with the activity depending on the size of the ester group of the L-alanine amino acid moiety. Methyl and ethyl derivatives (7a ClogP = 1.89; 7b ClogP = 2.42) showed better inhibitory activity (7a MIC = 62.5 mg/L; 7b MIC = 125 mg/L), whereas more hindered and lipophilic benzyl analogue (7d ClogP = 3.60) was found to be significantly less inhibitory (MIC = 250 mg/L). A possible reason for this finding could be due to the higher size of compound 7d that may prevent its entry inside the bacteria. Therefore, we postulate that the bioactivity against M. bovis BCG and M. tuberculosis H37Rv of phosphoroamidates 7a, 7b, 7c, 7g, 7h, 7i and 7l might result from better permeation through the mycobacterial cell wall due to an improved balance between their lipophilicity and molecular size. Potencies are moderate in this first series of compounds and subsequent work is required to optimize their biological activity; however, there is a clear antimycobacterial effect for some of these molecules. Notably, the parent nucleoside 2 was devoid of activity showing the crucial importance of the ProTide motif.
No homologues with significant sequence similarity with the protein ThyX of M. tuberculosis were found in E. coli. This could be a possible explanation for the inactivity of the compounds towards this organism.
Antiviral Activity
Parent nucleoside 2 and all synthesized phosphoramidates were also evaluated for their antiviral activity against varicella zoster virus (VZV), herpes simplex virus type 1 (HSV-1) and 2 (HSV-2), and human cytomegalovirus (HCMV), vaccinia virus (VV) according to previously described methods. 27 Phosphoroamidate 7h exhibited anti-VZV and anti-HSV activities in the low micromolar range (Table 3) .
However, although quite potent against a thymidine kinase positive (TK + ) strain of VZV, 7h was not active versus the thymidine kinase-deficient (TK -) strain. This showed the importance of this enzyme in the bioactivation of this class of molecules to its active species. Moreover, the lead compound, the L-alanine benzyloxy ester phosphoramidate with a phenyl aromatic group 7h, presented similar activity (EC 50 = 2.0 μM) to acyclovir (EC 50 = 2.6 μM) against VZV. 7h was also found to be active against HSV-1 and HSV-2 (EC 50 of 2 and 4 μM) but not against a TK -strain of HSV-1. In the case of 7a, 7c, 7d, the antiviral activity observed against VZV may be rather due to their underlying cytotoxicity. The compounds were not active against HCMV and VV (data not shown) in HEL cell cultures. 
Conclusion
A phosphoroamidate prodrug (ProTide) approach was used to seek to deliver the pre-formed bioactive monophosphate of a new compound recently reported to be a potent and selective inhibitor of thymidylate synthase X, an enzyme essential for the survival of M. tuberculosis. The lipophilic ProTide motif was designed to improve permeability trough the mycobacterial cell wall. We have successfully synthesized twelve phosphoroamidate derivatives of N-(3-(5-(2'-deoxyuridine-5'-monophosphate))prop-2-ynyl)octanamide 1, a potent in vitro ThyX inhibitors. Biological tests of our prodrugs showed antimycobacterial activity against M. tuberculosis H37Rv and M. bovis BCG in contrast to inactivity from the parent nucleoside. We considered that the increased lipophilicity together with the correct molecular size of phosphoroamidate derivatives 7a, 7b, 7c 7g, 7h 7i and 7l allowed them to penetrate through the mycobacterial cell wall liberating the monophosphate intracellulary and targeting their proposed biological target, ThyX protein.
Moreover, we found interesting activities against VZV for some of our compounds, showing the necessity of the pro-moiety to help transport of the drug into cells. We identified the Lalanine benzyl ester phosphoramidate with the phenyl aromatic group 7h as a potent antiviral agent, showing similar activity to acyclovir against VZV in this assay.
The results obtained highlight the possibility that the ProTide methodology could be used for the development of active molecules against TB and reveal the importance of improving lipophilicity to efficiently pass the mycobacteria wall barrier. To the best of our knowledge this is the first application of the ProTide technology to anti-mycobacterial agents. Further work is currently underway to enhance the potency of the new agents we herein report for the first time.
Experimental
Synthesis
Solvents and Reagents. The following anhydrous solvents were purchased from Sigma-Aldrich: dichloromethane (CH 2 Cl 2 ), tetrahydrofuran (THF), dimethylformamide (DMF), and any other reagents used. Amino acid esters commercially available were purchased from Novabiochem. All reagents commercially available were used without further purification. Propargylamide and octanoyl chloride were purchased from Aldrich whereas 5-iodo-2'-deoxyuridine from Berry & Associates.
Thin Layer Chromatography (TLC). Precoated aluminum backed plates (60 F254, 0.2 mm thickness, Merck) were visualized under both short and long wave ultraviolet light (254 and 366 nm) or by burning using the following TLC indicators: (i) molybdate ammonium cerium sulfate; (ii) potassium permanganate solution. Preparative TLC plates (20 cm × 20 cm, 500-2000 μm) were purchased from Merck.
Flash
Column Chromatography. Flash column chromatography was carried out using silica gel supplied by Fisher (60A, 35-70 μm). Glass columns were slurry packed using the appropriate eluent with the sample being loaded as a concentrated solution in the same eluent or preadsorbed onto silica gel. Fractions containing the product were identified by TLC, and pooled and the solvent was removed in vacuo.
High Performance Liquid Chromatography (HPLC).
The purity of the final compounds was verified to be >95% by HPLC analysis using either I) ThermoSCIENTIFIC, SPECTRA SYSTEM P4000, detector SPECTRA SYSTEM UV2000, Varian Pursuit XRs 5 C18, 150 x 4.6 mm (as an analytic column) or II) Varian Prostar (LC Workstation-Varian Prostar 335 LC detector), Thermo SCIENTIFIC Hypersil Gold C18, 5, 150 x 4.6 mm (as an analytic column). For the method of elution see the experimental part.
Nuclear Magnetic Resonance (NMR).
1 H NMR (500 MHz), 13 
Mass spectrometry (MS).
Low resolution mass spectra were performed on Bruker Daltonics microTof-LC, (atmospheric pressure ionization, electron spray mass spectroscopy) in positive mode.
Synthesis of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide 2
Propargyloctanamide (4). Propargylamine 3 (2.5 mL, 45.38 mmol) was dissolved in anhydrous CH 2 Cl 2 (113 mL) DIPEA (10.4 mL, 59.46 mmol) was added and the solution was cooled to 0 o C. Octanoyl chloride (8.52 mL, 49.92 mmol) was added dropwise and the reaction mixture was stirred at room temperature for 2 h. 
N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide (2).
A solution of 5-iodo-2'-deoxyuridine 5 (4.00 g, 11.29 mmol), alkyne 4 (6.14 g, 33.89 mmol), tetrakis Pd(PPh 3 ) 4 (1.30 g, 1.13 mmol), Cu(I)I (0.43 g, 2.26 mmol) and anhydrous DIPEA (3.93 mL, 22.58 mmol) in anhydrous DMF (75 mL) was stirred under an argon atmosphere at room temperature overnight. After this period, the solvent was removed under reduced pressure and the residue was suspended in CH 2 Cl 2 and stirred at room temperature for 2 h. The suspension was filtered and the solid was washed with CH 2 Cl 2 to give the desired compound as a light brown solid (91%, 4.20 g). For biological testing, the compound 2 was purified by preparative TLC using CH 2 Cl 2 /MeOH 9/1 as eluent. 1 To a solution of nucleoside 5 (1 mol/eq) and the appropriate phosphorochloridate 6a-l (3-5 mol/eq) in anhydrous THF, anhydrous NMI (5 mol/eq) was added dropwise and the reaction mixture was stirred at room temperature overnight. After this period, the solvent was removed under reduced pressure and the residue dissolved in CH 2 Cl 2 . The organic phase was washed with 0.5 M aqueous solution of citric acid, water and brine. The organic phase was dried over MgSO 4 , filtered and concentrated. The crude was purified by column chromatography using different eluting systems. Some of the compounds were further purified by preparative TLC using different eluting systems. All the compounds were recovered as a mixture of R P and S p diastereoisomers. .66 (C-1 'ipso' Naph, C-3 Naph, C-4 Naph, C-4a Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph), 116.47 (d, 3 J C-P = 2.9 Hz, C-2 Naph), 116.41 (d, 3 J C-P = 3.4 Hz, C-2 Naph), 100. 126 .52 (C-3 Naph, C-4 Naph, C-4a Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph), 116.42 (d, 3 J C-P = 3.4 Hz, C-2 Naph), 116.37 (d, 3 J C-P = 3.2 Hz, C-2 Naph), 100.24 (C-5), 90.33 (CH 2 C≡C), 87.40, 87.37 (C-1') .69 (C-3 Naph, C-4 Naph, C-4a Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph), 116.48 (d, 3 .65 (C-3 Naph, C-4 Naph, C-4a Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph, COOCH 2 Ph), 116.43 (d, 3 J C-P = 2.5 Hz, C-2 Naph), 100. 3H, H-3', H-5'), 4.16-4.01 (m, 4H, H-4', NHCH 2 C≡C, CHCH 3 ), 2.29 (ddd, J = 13.7 Hz, J = 6.0 Hz, J = 3.0 Hz, 0.5H of one diastereoisomer, H-2'), 2. 
N-{3-[5-(2'-Deoxy-5'-O-(1-naphthyl(ethyloxy-Lalaninyl)phosphate-uridine))]prop-2-ynyl)octanamide (7b
N-{3-[5-(2'-Deoxy-5'-O-(1-naphthyl(neopentyloxy-Lalaninyl)phosphate-uridine))] prop-2-ynyl)octanamide (7c
N-{3-[5-(2'-Deoxy-5'-O-(1-naphthyl(benzyloxy-Lalaninyl)phosphate-uridine))] prop-2-ynyl)octanamide (7d
N-{3-[5-(2'-Deoxy-5'-O-(phenyl(methoxy-Lalaninyl)phosphate-uridine))]prop-2-ynyl)octanamide (7e
Biological evaluation
Assay for antimycobacterial activity
M. tuberculosis H37Rv (ATCC27294) was grown in Middlebrook 7H9 broth supplemented with 0.02% (v/v) glycerol, 0.05% (v/v) tween-80 and 10% oleic acid, albumin, dextrose and catalase (OADC; BD Biosciences) as a stand culture at 37C. M. bovis BCG (ATCC35734) was grown in Middlebrook 7H9 broth supplemented with 0.02% (v/v) glycerol, 0.05% (v/v) tween-80 and 10% albumin, dextrose and catalase (ADC; BD Biosciences) in a roller bottle at 2 rpm at 37C. The antimycobacterial activities of the compounds were tested following the HTSPOTi. 28, 29 The high throughput growth inhibition assay was conducted in a semi-automated 96 well plate format as described previously. 26 Briefly, compounds dissolved in DMSO at a final concentration of 250 mg/L were serially diluted and dispensed in a volume of 2 µL into each well of a 96 well plate to which 200 µL of Middlebrook 7H10 agar medium kept at 55C supplemented with 0.05% (v/v) glycerol and 10% (v/v) OADC was added. A well with no compounds (DMSO only) and isoniazid were used as experimental controls. To all the plates, a drop (2 µL) of mycobacterial culture containing 2 X 10 3 colonyforming units (CFUs) was spotted in the middle of each well and the plates were incubated at 37C for up to two weeks. The minimum inhibitory concentrations (MICs) were determined as the lowest concentrations of the compound investigated where mycobacterial growth was completely inhibited by the presence of the compound.
Assay for antibacterial activity
E. coli DH5α (ATCC53868) was grown in Luria-Bertani broth (Oxoid, Thermoscientific) at 180 rpm as shaking culture with an incubation temperature of 37C. The antibacterial activities of the compounds were tested using the HT-SPOTi as mentioned earlier, using appropriate culture medium and growth conditions. The plates were incubated overnight following which observations were recorded.
Assay for antiviral activity
Cells. Human embryonic lung (HEL) fibroblasts were grown in minimum essential medium (MEM) supplemented with 10% inactivated fetal calf serum (FCS), 2 mM L-glutamine, and 0.3% sodium bicarbonate.
Viruses. The laboratory wild-type varicella zoster virus (VZV) strain Oka, the thymidine kinase-deficient VZV strain 07-1, herpes simplex virus (HSV-1, KOS), (HSV-2, G), the thymidine kinase-deficient (ACV R ) HSV-1 strain B-2006, human cytomegalovirus (HCMV) strains Davis and AD-169, and vaccinia virus (VV) were used in the virus inhibition assays.
Confluent HEL cell cultures grown in 96-well microtiter plates were inoculated with VZV at an input of 20 plaque forming units (PFU) per well or with HCMV at an input of 100 PFU per well. Confluent HEL cell cultures were inoculated with HSV at 100 CCID 50 (50% cell culture infective dose) per well. After a 1-2 h incubation period, residual virus was removed and the infected cells were further incubated with MEM (supplemented with 2% inactivated FCS, 2 mM L-glutamine, and 0.3% sodium bicarbonate) containing varying concentrations of the compounds. Antiviral activity was expressed as EC 50 (50% effective concentration), or compound concentration required to reduce viral plaque formation after 5 days (varicella zoster virus (VZV)) or virus-induced cytopathicity (HCMV after 7 days and HSV, VV after 3 days) by 50% compared to the untreated control.
Assay for eukaryotic cell toxicity
Confluent monolayers of HEL cells as well as growing HEL cells in 96-well microtiter plates were treated with different concentrations of the experimental drugs. Cell cultures were incubated for 3 (growing cells) or 5 (confluent cells) days. At the indicated time, the cells were trypsinized, and the cell number was determined using a Coulter counter (Beckman, Analis, Suarlée, Belgium). The 50% cytostatic concentration (CC 50 ) was defined as the compound concentration required to reduce the cell number by 50%.
